When should Hemlibra (emicizumab) be held in an 88-year-old patient with non‑resolving pneumonia?

When to Hold Hemlibra in an 88-Year-Old with Non-Resolving Pneumonia

Hemlibra (emicizumab) should generally NOT be held during pneumonia treatment in this patient, as there is no evidence-based indication to discontinue prophylactic hemophilia therapy during infection. The focus should be on optimizing pneumonia management while maintaining bleeding prophylaxis.

Key Clinical Reasoning

Why Hemlibra Should Continue

• No drug interaction with antibiotics: The FDA label for Hemlibra does not list any contraindications or interactions with antimicrobial therapy 1
• Subcutaneous administration advantage: Unlike IV factor replacement, Hemlibra does not require venous access that could complicate pneumonia management 1
• Bleeding risk during illness: Elderly patients with severe infections may have increased bleeding risk from procedures (blood draws, IV lines, potential invasive diagnostics) and the stress of acute illness
• Long half-life considerations: Hemlibra has a prolonged half-life, so discontinuation would not provide immediate benefit even if theoretically desired 1

When to Consider Holding (Rare Scenarios)

Only hold Hemlibra if:

1. Thrombotic complications develop - particularly if activated prothrombin complex concentrate (aPCC) is needed for breakthrough bleeding, as this combination carries thrombotic microangiopathy and thromboembolism risk 1
2. Severe drug reaction - rash, urticaria, or angioedema attributed to emicizumab 1
3. Planned major invasive procedure requiring aPCC use - coordinate with hematology 1

Managing the Non-Resolving Pneumonia

The priority is addressing why the pneumonia is not resolving, not adjusting hemophilia prophylaxis.

Assessment Timeline

Non-responding pneumonia within first 72 hours suggests 2:

• Antimicrobial resistance
• Unusually virulent organism
• Wrong diagnosis
• Host defense defect (consider immunosuppression in elderly)

Non-response after 72 hours typically indicates 2:

• Complication (empyema, abscess, parapneumonic effusion)
• Need for full reinvestigation

Specific Actions for This Patient

1. Comprehensive clinical review 3:

   • Repeat chest radiograph
   • C-reactive protein and white cell count on days 3-4
   • Blood cultures if not already obtained
   • Sputum culture with microscopy (>25 PMNs, <10 squamous cells per low-power field) 4

2. Consider risk factors for resistant organisms in an 88-year-old:

   • Pseudomonas aeruginosa risk if ≥2 of: recent hospitalization, frequent antibiotics (>4 courses/year or within 3 months), severe underlying disease, oral steroids >10mg prednisone daily 2
   • Aspiration pneumonia if history of dysphagia, stroke, or altered consciousness 2

3. Antibiotic adjustment (not Hemlibra adjustment):

   • For non-severe pneumonia failing initial therapy: add or substitute macrolide 3
   • For severe pneumonia not responding: consider adding rifampicin 3
   • If Pseudomonas suspected: ciprofloxacin or levofloxacin 750mg/24h, or IV antipseudomonal β-lactam 2

Laboratory Monitoring Considerations

Important caveat: Hemlibra interferes with aPTT-based coagulation tests 1. If coagulation monitoring is needed during pneumonia management:

• Use chromogenic or immunoassay-based tests - these are unaffected by Hemlibra
• Do NOT use: aPTT, ACT, one-stage factor VIII assays, or aPTT-based single-factor assays 1
• Inform laboratory that patient is on emicizumab to ensure appropriate test selection

Common Pitfalls to Avoid

1. Do not reflexively hold hemophilia prophylaxis during infection without specific indication
2. Do not use aPCC (activated prothrombin complex concentrate) for breakthrough bleeding without hematology consultation due to thrombotic risk with Hemlibra 1
3. Do not delay pneumonia reinvestigation beyond 72 hours if no clinical improvement 2
4. Do not assume typical pneumonia presentation in elderly patients - may present with falls, confusion, or decompensation of chronic disease 5

Practical Algorithm

Non-resolving pneumonia in patient on Hemlibra:
├─ Continue Hemlibra (default)
├─ Reassess pneumonia at 72 hours
│  ├─ Full clinical review
│  ├─ Repeat imaging and labs
│  └─ Adjust antibiotics based on findings
├─ Monitor for Hemlibra-specific complications
│  ├─ Thrombotic events (rare, especially with aPCC)
│  └─ Injection site reactions
└─ Hold Hemlibra ONLY if:
   ├─ Thrombotic complication develops
   ├─ aPCC required for bleeding
   └─ Severe drug reaction to emicizumab

The clinical focus should be on aggressive pneumonia management with appropriate antibiotic escalation and diagnostic workup, not on holding prophylactic hemophilia therapy.